1. Home
  2. RBKB vs AGEN Comparison

RBKB vs AGEN Comparison

Compare RBKB & AGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

RBKB

Rhinebeck Bancorp Inc.

HOLD

Current Price

$11.96

Market Cap

130.0M

Sector

Finance

ML Signal

HOLD

Logo Agenus Inc.

AGEN

Agenus Inc.

HOLD

Current Price

$4.67

Market Cap

126.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
RBKB
AGEN
Founded
1860
1994
Country
United States
United States
Employees
N/A
N/A
Industry
Banks
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
130.0M
126.2M
IPO Year
2019
2000

Fundamental Metrics

Financial Performance
Metric
RBKB
AGEN
Price
$11.96
$4.67
Analyst Decision
Buy
Analyst Count
0
2
Target Price
N/A
$14.50
AVG Volume (30 Days)
7.0K
738.6K
Earning Date
01-29-2026
11-10-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
0.46
N/A
Revenue
$45,306,000.00
$106,829,000.00
Revenue This Year
N/A
$23.68
Revenue Next Year
N/A
$23.17
P/E Ratio
$26.17
N/A
Revenue Growth
54.93
N/A
52 Week Low
$9.31
$1.38
52 Week High
$13.99
$7.34

Technical Indicators

Market Signals
Indicator
RBKB
AGEN
Relative Strength Index (RSI) 46.99 74.42
Support Level $11.56 $3.01
Resistance Level $12.10 $4.00
Average True Range (ATR) 0.32 0.26
MACD -0.10 0.18
Stochastic Oscillator 18.68 87.34

Price Performance

Historical Comparison
RBKB
AGEN

About RBKB Rhinebeck Bancorp Inc.

Rhinebeck Bancorp Inc is the holding company for Rhinebeck Bank which provides a full range of banking and financial services to consumer and commercial customers. Financial services, including investment advisory and financial product sales, are offered through a division of the Bank doing business as Rhinebeck Asset Management (RAM). The Bank's primary business activity is accepting deposits from the general public and using those funds to originate indirect automobile loans (automobile loans referred by automobile dealerships), commercial real estate loans (which include multi-family real estate loans and commercial construction loans), commercial business loans and one-to four-family residential real estate loans, and to purchase investment securities.

About AGEN Agenus Inc.

Agenus Inc is an American clinical-stage company with a pipeline of therapies designed to activate the body's immune system to fight cancer and infections, including immune-modulatory antibodies, adoptive cell therapies through its subsidiary MiNK Therapeutics Inc. and vaccine adjuvants through its subsidiary SaponiQx Inc. This robust product pipeline is supported by company's in-house capabilities, including current good manufacturing practice (cGMP) manufacturing and a clinical operations platform. The company's antibody candidates are botensilimab (a proprietary next-generation Fc-engineered CTLA-4 antibody, also known as AGEN1811) and balstilimab (a PD-1 antibody).

Share on Social Networks: